---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-038742"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T20:33:25.215883+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics reports FY2024 net loss $93.4M; ENLIGHTEN 2 top-line data expected Q2 2025

## Summary
- Net loss for FY2024 was $93.4M ($1.43 diluted EPS) vs $62.7M in FY2023; cash $40.6M as of Dec 31, 2024.
- Top-line results from ENLIGHTEN 2 Phase 3 trial of LYR-210 in CRS expected in Q2 2025.
- Positive post-hoc data from ENLIGHTEN 1 extension in polyp cohort; FDA alignment on registration path for CRSwNP.
- Planned reverse stock split to maintain Nasdaq listing; requires shareholder approval in Q2 2025.
- R&D expenses decreased to $43.8M from $48.0M due to trial completions and workforce reduction.

## SEC filing metadata
- accession: 0000950170-25-038742
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017025038742/0000950170-25-038742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017025038742/lyra-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-038742
- JSON: https://secwatch.observer/filing/0000950170-25-038742.json
- Plain text: https://secwatch.observer/filing/0000950170-25-038742.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.